Best Practices for In-Use Stability Testing of Biologics

In-use stability testing is a critical component of biopharmaceutical product development, particularly for formulations that are reconstituted before use, presented in multi-dose vials, or administered through infusion devices. These studies simulate real-world handling conditions post-opening or reconstitution to ensure product quality, safety, and efficacy are maintained during clinical or home use. This tutorial outlines how to design, execute, and interpret in-use stability protocols for biologics in alignment with regulatory guidelines.

What Is In-Use Stability Testing?

In-use stability testing refers to the evaluation of a drug product’s stability after its immediate container is opened, its seal is punctured, or its contents are reconstituted, diluted, or transferred prior to administration.

Goals of In-Use Testing:

• Ensure product retains potency and physical integrity
• Confirm microbiological stability over the in-use period
• Support labeling claims (e.g., “Use within 24 hours after opening”)
• Evaluate container closure integrity after multiple punctures

Regulatory Framework

Global regulatory agencies recognize and require in-use stability data when warranted by the dosage form. Key references include:

• ICH Q5C: Stability Testing of Biotech Products
• EMA Guideline: In-use Stability Testing of Multidose Containers
• USP : Pharmaceutical Compounding—Sterile Preparations
• WHO TRS 992 Annex 3: Stability Testing of Active Pharmaceutical Ingredients and Finished Products

These emphasize that in-use periods must be justified by study data simulating real-world storage and handling conditions.

When Is In-Use Stability Testing Required?

• For multi-dose vials with multiple withdrawals
• For reconstituted lyophilized products
• For products diluted prior to infusion (e.g., monoclonal antibodies)
• For prefilled syringes stored after opening
• For devices requiring reusability or dose tracking

Step-by-Step Protocol for In-Use Stability Testing

Step 1: Define Use-Case and Risk Profile

Design studies based on how the product will be used in real-world conditions:

• Single withdrawal vs. repeated puncture
• Time between first use and final dose
• Environmental exposure (e.g., temperature, light)
• Aseptic technique and microbial contamination risk

Include worst-case scenarios based on labeling and clinical instructions.

Step 2: Prepare Test Articles

Use representative batches (preferably commercial scale) in the final container-closure system. Simulate common manipulations such as:

• Reconstitution with approved diluent (e.g., water for injection)
• Withdrawal using sterile needles or infusion pumps
• Storage in refrigerator (2–8°C) or room temperature (25°C) post-use

Step 3: Select Timepoints and Storage Conditions

Choose time intervals reflecting the intended in-use period. Common timepoints include:

• 0, 6, 12, 24, 48, and 72 hours post-opening or reconstitution
• 7 and 14 days for longer use durations (e.g., weekly doses)

Store test units under specified post-use conditions (e.g., 2–8°C, ambient, protected from light).

Step 4: Monitor Critical Quality Attributes

Use stability-indicating, validated analytical methods to evaluate:

• Potency: Bioassay or ELISA
• Purity and aggregates: SEC, SDS-PAGE
• pH and appearance: Color, clarity, particulates
• Sterility or microbial growth: Especially for multi-use vials
• Preservative content: If applicable (e.g., phenol, benzyl alcohol)

Include controls stored under standard conditions for comparison.

Step 5: Simulate Multiple Withdrawals and Usage

For multi-dose or punctured vials:

• Use standard gauge needles (e.g., 21G or 25G) for punctures
• Replicate the number of expected withdrawals (e.g., 10-dose vial = 10 punctures)
• Assess stopper resealability and integrity post-use

Include container closure integrity testing if microbial ingress is a risk.

Step 6: Document and Evaluate Results

Assess whether quality attributes remain within specification for the entire in-use period. For example:

• Potency must remain ≥90% of label claim
• No visible signs of contamination or color change
• Microbial counts must meet USP / or pass sterility

If the product degrades or becomes unsafe before the intended duration, revise the in-use period accordingly.

Labeling and Regulatory Implications

Results from in-use studies directly support labeling claims such as:

• “Use within 24 hours after reconstitution”
• “Store between 2–8°C after opening; discard after 7 days”
• “Do not freeze after reconstitution”

Submit the in-use stability data in CTD Module 3.2.P.8 and reference SOPs from systems like Pharma SOP for ongoing product lifecycle management.

Case Study: In-Use Stability of a Reconstituted Monoclonal Antibody

A lyophilized monoclonal antibody was reconstituted with sterile water and stored at 2–8°C for 48 hours post-use. Stability testing was performed at 0, 12, 24, and 48 hours. Potency remained ≥97%, with no visible particles or pH shift. Microbial testing confirmed sterility post multiple punctures. Based on the data, the product was labeled: “Use within 48 hours after reconstitution. Store at 2–8°C. Do not freeze.”

Checklist: In-Use Stability Testing for Biologics

1. Identify the in-use scenario: reconstitution, dilution, or puncture
2. Select appropriate storage conditions and durations
3. Simulate usage with validated, aseptic techniques
4. Analyze for potency, purity, visual appearance, and microbial growth
5. Include multiple withdrawals if applicable
6. Define and justify the in-use period in product labeling

Common Mistakes to Avoid

• Assuming in-use stability without supporting data
• Skipping microbial testing for multidose vials
• Using non-representative containers or sampling techniques
• Failing to monitor preservative degradation or loss

Conclusion

In-use stability testing ensures that biologic products remain safe and effective throughout their period of use following opening, reconstitution, or dilution. By following a scientifically rigorous protocol and aligning with regulatory expectations, manufacturers can establish appropriate in-use durations, reduce patient risk, and support label claims. For validated test plans, aseptic sampling SOPs, and microbial protocols, visit Stability Studies.